# Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy

> **NCT00646178** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 102 (actual)

## Conditions studied

- Arthritis
- Psoriatic

## Interventions

- **DRUG:** adalimumab
- **DRUG:** placebo for adalimumab

## Key facts

- **NCT ID:** NCT00646178
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2004-03
- **Final completion:** —
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2008-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00646178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00646178, "Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00646178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*